TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03276533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study: NCT04349787

Intervention type: OTHER
Intervention: Computer-aided diagnosis (CADx)
Description: Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.

Intervention type: OTHER
Intervention: BLI Adenoma Serrated International Classification (BASIC)
Description: Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
Study: NCT04749810

Intervention type: DRUG
Intervention: Elizaria®
Description: Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
Study: NCT04073693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acids (BRCA)
Description: They were with BRCA during the day apart of following the standard recommendations

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Branched chain amino acids (BRCA)
Description: They were with BRCA during the day apart of following the standard recommendations
Study: NCT02930109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-200
Description: During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
Study: NCT03398928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture added to usual care
Study: NCT00736099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptine 5 mg
Description: safety and efficacy of linagliptine 5 mg open label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptine 5 mg and pioglitazone 30 mg
Description: efficacy and safety of the combination linagliptine and pioglitazone
Study: NCT02801851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREEN-ED
Description: SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
Study: NCT03068910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study: NCT02605083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: Will be given orally once or twice daily. Each treatment cycle = 21 days.
Study: NCT01695798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable polio vaccine and Bivalent oral polio vaccine
Description: One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable polio vaccine and Bivalent oral polio vaccine
Description: One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone
Study: NCT02887482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5700
Description: GLS 5700 at 2 mg DNA/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01560091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silodosin
Description: 8mg PO Qday

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extra-corporeal shock wave lithotripsy
Description: ESWL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-corporeal shock wave lithotripsy
Description: ESWL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-corporeal shock wave lithotripsy
Description: ESWL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg PO Qday
Study: NCT02290028

Intervention type: DEVICE
Group type: OTHER
Intervention: Sentus QP left ventricular lead
Description: Implantation of quadripolar left ventricular lead in patients with CRT-D indication
Study: NCT02661282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Description: Given IV
Study: NCT03744156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment-Insomnia
Description: 8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Education
Description: 8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
Study: NCT04069975

Intervention type: OTHER
Intervention: Sedation
Description: The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
Study: NCT04153266

Intervention type: OTHER
Intervention: No intervention is planned for this study
Description: No intervention was/is planned for this study. The study is questionnaire-based (observational).
Study: NCT01812707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening
Study: NCT02661282

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01812707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening
Study: NCT03605745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Vapor Ablation
Description: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.
Study: NCT02661282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03918733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: surgical treatment will be done of failed root canal treated teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical retreatment
Description: Non surgical retreatment will be done.
Study: NCT02025023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil Injection
Description: If the chalazion is present at follow-up visit, another injection of 5-FU will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: If chalazion present at follow-up, another Triamcinolone injection will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Curettage
Description: If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Curettage
Description: If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Curettage
Description: If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
Study: NCT04349176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose
Description: Randomized to either 100U or 155U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose
Description: Randomized to either 100U or 155U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose
Description: Randomized to either 100U or 155U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose
Description: Randomized to either 100U or 155U
Study: NCT02122471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02082262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
Study: NCT04463277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding with Calorie Restriction
Description: Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
Study: NCT01293409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Brain-Targeted Bright Light Treatment
Description: Transcranial Brain-Targeted Bright Light Treatment via Ear Canals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Brain-Targeted Bright Light Treatment
Description: Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
Study: NCT02393079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (TCLT)
Description: Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
Study: NCT01293409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Brain-Targeted Bright Light Treatment
Description: Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
Study: NCT02980328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level light therapy
Description: we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study: NCT04438629

Intervention type: DRUG
Intervention: COVID-19 treatment
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.

Intervention type: DRUG
Intervention: COVID-19 treatment
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.

Intervention type: DRUG
Intervention: COVID-19 treatment
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
Study: NCT03549663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
Study: NCT01399125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch
Description: Once-daily target patch size 10 cm²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine Capsules
Description: Twice-daily target dose of 6 mg oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Rivastigmine patch
Description: Matching placebo to Rivastigmine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Rivastigmine capsules
Description: matching Placebo to Rivastigmine capsules
Study: NCT01050673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VERSAJET
Description: Hydro-surgery debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel or blade
Description: Conventional Surgical Debridement
Study: NCT03039582

Intervention type: DIAGNOSTIC_TEST
Intervention: Bidigital palpation
Description: palpation of the anovaginal distance with two fingers

Intervention type: DIAGNOSTIC_TEST
Intervention: Bidigital palpation
Description: palpation of the anovaginal distance with two fingers

Intervention type: DIAGNOSTIC_TEST
Intervention: Bidigital palpation
Description: palpation of the anovaginal distance with two fingers

Intervention type: DIAGNOSTIC_TEST
Intervention: Perineal ultrasound
Description: ultrasound measurement of the anovaginal distance

Intervention type: DIAGNOSTIC_TEST
Intervention: Perineal ultrasound
Description: ultrasound measurement of the anovaginal distance

Intervention type: DIAGNOSTIC_TEST
Intervention: Perineal ultrasound
Description: ultrasound measurement of the anovaginal distance